AbbVie (NYSE:ABBV) Issues FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 13.910-14.110 for the period, compared to the consensus estimate of 14.250. The company issued revenue guidance of -. AbbVie also updated its Q2 2026 guidance to 3.570-3.610 EPS.

AbbVie Stock Performance

Shares of ABBV stock traded up $3.40 during trading hours on Tuesday, reaching $258.15. The company had a trading volume of 643,155 shares, compared to its average volume of 7,167,084. AbbVie has a 12-month low of $184.63 and a 12-month high of $261.64. The company has a market capitalization of $456.11 billion, a price-to-earnings ratio of 127.43, a PEG ratio of 0.86 and a beta of 0.30. The stock has a fifty day moving average of $221.27 and a 200-day moving average of $220.47.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 earnings per share. On average, analysts forecast that AbbVie will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s payout ratio is presently 340.89%.

Wall Street Analyst Weigh In

ABBV has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price objective on shares of AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a research report on Tuesday, June 23rd. Morgan Stanley boosted their target price on shares of AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Cantor Fitzgerald lifted their price target on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Guggenheim reiterated a “buy” rating and issued a $249.00 price objective on shares of AbbVie in a research report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a European Commission approval for TEPKINLY (epcoritamab) plus lenalidomide and rituximab to treat relapsed or refractory follicular lymphoma. The approval expands the drug’s reach in Europe and supports AbbVie’s oncology growth story. Article: AbbVie Announces TEPKINLY approval by the European Commission
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 and kept an overweight rating, signaling continued analyst confidence in the stock’s upside. Article: AbbVie price target raised by Cantor Fitzgerald
• Neutral Sentiment: AbbVie is also getting some investor focus ahead of its upcoming quarterly report, with analysts watching whether Skyrizi and Rinvoq can offset continued pressure from Humira declines. Article: Will Immunology Franchise Aid AbbVie’s Upcoming Q2 Results?
• Negative Sentiment: AbbVie cut its second-quarter 2026 EPS guidance to $3.57-$3.61, below the consensus estimate of $3.77, which could pressure shares. FY 2026 EPS guidance was also lowered to $13.91-$14.11 versus the Street’s $14.25 forecast.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Wellington Management Group LLP grew its stake in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Raymond James Financial Inc. raised its stake in shares of AbbVie by 41.8% during the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Amundi grew its position in AbbVie by 15.6% in the 3rd quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares during the last quarter. State Street Corp grew its position in AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock valued at $18,494,193,000 after buying an additional 1,119,274 shares during the last quarter. Finally, First Trust Advisors LP increased its stake in AbbVie by 170.2% in the 4th quarter. First Trust Advisors LP now owns 1,336,498 shares of the company’s stock valued at $305,377,000 after buying an additional 841,947 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.